.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,476,669

« Back to Dashboard

Claims for Patent: 5,476,669

Title: Method for treatment of gastro intestinal disorders
Abstract:A method is disclosed for preventing the recurrence of duodenal ulcer associated with Campylobacter pylori (Helicobacter pylori) infection in a patient suffering from duodenal ulcer disease associated with Campylobacter pylori infection by administering a pharmaceutically acceptable bismuth compound, a first antibiotic selected from the group consisting of tetracycline and penicillins, and a second antibiotic which is metronidazole.
Inventor(s): Borody; Thomas J. (Five Dock, AU)
Assignee: Examed Australia Pty. Ltd. (New South Wales, AU) Ostapat Pty. Limited (New South Wales, AU) Gastro Services Pty. Limited (New South Wales, AU) Capability Services Pty. Limited (New South Wales, AU)
Application Number:07/937,421
Patent Claims: 1. A method of preventing recurrence of gastric ulcer associated with Campylobacter pylori (Helicobacter pylori) infection in a patient suffering from gastric ulcer disease associated with Campylobacter pylori (Helicobacter pylori) infection, said method comprising administering to said patient Campylobacter pylori infection eradicating amounts of pharmaceutically acceptable bismuth compound, first antibiotic selected from the group consisting of tetracycline and penicillins, and second antibiotic which is metronidazole.

2. A method as set forth in claim 1 further comprising a step of administering to said patient an effective amount of a gastric acid suppressant for a predetermined length of time.

3. The method as set forth in claim 2 wherein said predetermined length of time is three to twenty-eight days followed by an administration of said bismuth compound/antibiotics combination.

4. The method as set forth in claim 2 wherein said gastric acid suppressant is an histamine.sub.2 -receptor antagonist.

5. The method as set forth in claim 2 wherein said gastric acid suppressant is a benzimidazole.

6. The method as set forth in claim 5 wherein said benzimidazole is lansoprazole or omeprazole.

7. The method as set forth in claim 2 wherein said gastric acid suppressant is a prostaglandin.

8. The method as set forth in claim 2 wherein said gastric acid suppressant is a proton pump inhibitor.

9. The method as set forth in claim 2 wherein said gastric acid suppressant is a K/Na ATP-ase inhibitor.

10. A method of treating a patient with gastric ulcer associated with Campylobacter pylori (Helicobacter pylori) infection, said method comprising administering to said patient acid suppressant in an amount effective to obtain symptomatic relief and ulcer epithelialization before or during administering to said patient of Campylobacter pylori (Helicobacter pylori) infection eradication amounts of pharmaceutically acceptable bismuth compound, first antibiotic selected from the group consisting of tetracycline and penicillins, and second antibiotic which is metronidazole.

11. A method as set forth in claim 10 further comprising a step of administering to said patient an effective amount of a gastric acid suppressant for a predetermined length of time.

12. The method as set forth in claim 11 wherein said predetermined length of time is three to twenty-eight days followed by an administration of said bismuth compound/antibiotics combination.

13. The method as set forth in claim 11 wherein said gastric acid suppressant is an histamine.sub.2 -receptor antagonist.

14. The method as set forth in claim 11 wherein said acid suppressant is a benzimidazole.

15. The method as set forth in claim 14 wherein said benzimidazole is either lansoprazole or omeprazole.

16. The method as set forth in claim 11 wherein said gastric acid suppressant is a prostaglandin.

17. The method as set forth in claim 11 wherein said gastric acid suppressant is a proton pump inhibitor.

18. The method as set forth in claim 11 wherein said gastric acid suppressant is a K/Na ATP-ase inhibitor.

19. A method of preventing recurrence of duodenal ulcer associated with Campylobacter pylori (Helicobacter pylori) infection in a patient suffering from duodenal ulcer disease associated with Campylobacter pylori (Helicobacter pylori) infection, said method comprising administering to said patient Campylobacter pylori (Helicobacter pylori) infection eradicating amounts of a pharmaceutically acceptable bismuth compound, a first antibiotic selected from the group consisting of tetracycline and penicillins and a second antibiotic which is metronidazole and further comprising a step of administering to said patient an effective amount of a gastric acid suppressant for a predetermined length of time.

20. The method as set forth in claim 19 wherein said predetermined length of time of administration of said gastric acid suppressant is three to twenty-eight days followed by an administration of said bismuth compound/antibiotics combination.

21. The method as set forth in claim 19 wherein said gastric acid suppressant is an histamine.sub.2 -receptor antagonist.

22. The method as set forth in claim 19 wherein said acid suppressant is a benzimidazole.

23. The method as set forth in claim 22 wherein said benzimidazole is either lansoprazole or omeprazole.

24. The method as set forth in claim 19 wherein said gastric acid suppressant is a prostaglandin.

25. The method as set forth in claim 19 wherein said gastric acid suppressant is a proton pump inhibitor.

26. The method as set forth in claim 19 wherein said gastric acid suppressant is a K/Na ATP-ase inhibitor.

27. A method of treating a patient with duodenal ulcer associated with Campylobacter pylori (Helicobacter pylori) said method comprising administering to said patient a gastric acid suppressant in an amount and for a time effective to obtain symptomatic relief and ulcer epithelialization before or during administering to said patient of Campylobacter pylori (Helicobacter pylori) infection eradicating amounts of a pharmaceutically acceptable bismuth compound, a first antibiotic selected from the group consisting of tetracycline and penicillins and a second antibiotic which is metronidazole, thereby to cause healing of said duodenal ulcer as well as to prevent recurrence thereof.

28. The method as set forth in claim 27 wherein said predetermined length of time of administration of said gastric acid suppressant is three to twenty-eight days followed by an administration of said bismuth compound/antibiotics combination.

29. The method as set forth in claim 27 wherein said gastric acid suppressant is an histamine.sub.2 -receptor antagonist.

30. The method as set forth in claim 27 wherein said acid suppressant is a benzimidazole.

31. The method as set forth in claim 28 wherein said benzimidazole is either lansoprazole or omeprazole.

32. The method as set forth in claim 27 wherein said gastric acid suppressant is a prostaglandin.

33. The method as set forth in claim 27 wherein said gastric acid suppressant is a proton pump inhibitor.

34. The method as set forth in claim 27 wherein said gastric acid suppressant is a K/Na ATP-ase inhibitor.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc